1. The document profiles the top ten CEOs including Jeff Bezos of Amazon, John Martin of Gilead Sciences, and John Chambers of Cisco Systems.
2. It provides a brief overview of each CEO and the company they lead, focusing on the industry, operations, size and acquisitions of the various technology, pharmaceutical and agricultural firms.
3. The CEOs represented work for major multinational corporations including Amazon, Gilead Sciences, Cisco, Allergan, Simon Property Group, Novo Nordisk, Monsanto, Valeant Pharmaceuticals, Precision Castparts and PotashCorp.
Biomedical engineering or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes.
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann.docxchristiandean12115
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann Utterback, Robin Chapman, Gail Christian
Arizona State Unive rsity
Introduction
Valeant Pharmaceut icals International, Inc. pro -
motes itself as a multinational specialty pharmaceuti-
cal company with a diverse product portfolio focusing
on branded pharmaceuticals , branded and unbranded
generics, and over-the- counter (OTC) products special-
izing in neurology and dermatology.1 Product sales focus
on North America, Central Europe, Mexico, Brazil, and
Australia, with manufacturing sites in Canada, Brazil,
Poland, and Mexico. 2
In his 2006 me ssa ge to shareholders, Timothy
C. Tyson, then president and CEO, reflected , "In
many ways, 2006 was a life-changing year for Valeant
Pharmaceuticals. It was a challenging year-one that
certainly stretched us and tested our resolve. "3 That
was the year that Valeant lost its chairman, Robert
W. O'Leary, to cancer. Valeant would face a new set
of challenges in the fall of 2010, when it merged with
Canada's Biovail Corporation. Although Valeant even -
tually recovered fro m the loss of chairman Robert
W. O'Leary, would it be able to overcome the challenges
of the merger and strategically position itself to capture a
significant portion of the global pharmaceutical market
that was expected to reach $1.1 trillion by 2014?4
Although we give a brief history of Valeant here,
this case focuses on the Biovail merger and Valeant's
neurology division . This division manufactures
and markets products to treat Parkinson's disease
(PD), epilepsy, migraines, depression , chronic pain,
Huntington's disease , and myasthenia gravis. A central
question is whether Valeant will be able to capitalize
on an aging population's growing demand for its new
epilepsy drug, retigabine, and its other products. Also ,
due to significant restructuring efforts occurring before
and resulting from the merger, an important question
is whether the changes will yield the benefits promised
to sha~eholders ·and enable the firm to compete more
effectively. The answers to these questions and others
will influence Valeant's future success.
History
Valeant Pharmaceuticals was founded in 1960 by
Milan Panic, a Yugoslav defector. The company started
in California and was originally called Intern ational
Chemical & Nuclear Corp. (ICN) . Panic ran the
company for 43 years. 5 Initially, the company's primary
business involved chemical and drug sales, but it grew
through acquisitions of small drug companies. In 1963,
the company launched its IP0 .6
In 1970, ICN scientists discovered ribavirin, and in
1985, it received US Food and Drug Administration (FDA)
approval for the drug to be used as a treatment for lung
infections in children. As a blockbuster drug, ribavirin
powered ICN's growth and reputation for decades .7 In
later years, Panic directed ICN to promote ribavirin as
a treatment for AIDS and hepatitis C.8 During the 70s,
ri.
Biomedical engineering or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes.
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann.docxchristiandean12115
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann Utterback, Robin Chapman, Gail Christian
Arizona State Unive rsity
Introduction
Valeant Pharmaceut icals International, Inc. pro -
motes itself as a multinational specialty pharmaceuti-
cal company with a diverse product portfolio focusing
on branded pharmaceuticals , branded and unbranded
generics, and over-the- counter (OTC) products special-
izing in neurology and dermatology.1 Product sales focus
on North America, Central Europe, Mexico, Brazil, and
Australia, with manufacturing sites in Canada, Brazil,
Poland, and Mexico. 2
In his 2006 me ssa ge to shareholders, Timothy
C. Tyson, then president and CEO, reflected , "In
many ways, 2006 was a life-changing year for Valeant
Pharmaceuticals. It was a challenging year-one that
certainly stretched us and tested our resolve. "3 That
was the year that Valeant lost its chairman, Robert
W. O'Leary, to cancer. Valeant would face a new set
of challenges in the fall of 2010, when it merged with
Canada's Biovail Corporation. Although Valeant even -
tually recovered fro m the loss of chairman Robert
W. O'Leary, would it be able to overcome the challenges
of the merger and strategically position itself to capture a
significant portion of the global pharmaceutical market
that was expected to reach $1.1 trillion by 2014?4
Although we give a brief history of Valeant here,
this case focuses on the Biovail merger and Valeant's
neurology division . This division manufactures
and markets products to treat Parkinson's disease
(PD), epilepsy, migraines, depression , chronic pain,
Huntington's disease , and myasthenia gravis. A central
question is whether Valeant will be able to capitalize
on an aging population's growing demand for its new
epilepsy drug, retigabine, and its other products. Also ,
due to significant restructuring efforts occurring before
and resulting from the merger, an important question
is whether the changes will yield the benefits promised
to sha~eholders ·and enable the firm to compete more
effectively. The answers to these questions and others
will influence Valeant's future success.
History
Valeant Pharmaceuticals was founded in 1960 by
Milan Panic, a Yugoslav defector. The company started
in California and was originally called Intern ational
Chemical & Nuclear Corp. (ICN) . Panic ran the
company for 43 years. 5 Initially, the company's primary
business involved chemical and drug sales, but it grew
through acquisitions of small drug companies. In 1963,
the company launched its IP0 .6
In 1970, ICN scientists discovered ribavirin, and in
1985, it received US Food and Drug Administration (FDA)
approval for the drug to be used as a treatment for lung
infections in children. As a blockbuster drug, ribavirin
powered ICN's growth and reputation for decades .7 In
later years, Panic directed ICN to promote ribavirin as
a treatment for AIDS and hepatitis C.8 During the 70s,
ri.
Food Packaging Companies PPT: Business Opportunity & OverviewIMARC Group
Food packaging assists in preserving and transporting food products to their desired location without affecting their taste or quality. It also aids in protecting food products from bacteria, spillage, moisture and toxins.
From Startup to Blue Chip: The Success Story of Gilead Sciences Inc.RobertsDissertation
"Gilead Sciences (GILD) is a biotechnology company that generally focuses on antiviral drugs and therapies for HIV, hepatitis B and influenza. The company was founded in 1987 by Michael Riordan, a medical doctor who went to Harvard."
Investopedia, 2015.
USA Medical Device report 2015. In this report you can find the detail information about USA medical device industry with Merger and acquisition , Research & Development, Geographical breakdown for U.S. medical device sector.
Tech M&A Monthly: Ten Steps to Successfully Sell Now - May 2013Corum Group
Record cash, strong public markets and disruptive technology are all helping make this the best time to sell a software or related tech firm since 1999. But how do you take advantage? In this special webcast, Corum CEO Bruce Milne will present "10 Steps To Successfully Sell Now" drawing on his three decades of experience selling technology companies to help you translate your hard work and technical genius into real personal wealth, at one of the most opportune times in recent history.
HealthXL is the global clearing house for innovation in healthcare. We catalyse collaboration between leading brands in healthcare and the most exciting tech companies to improve the lives of millions of people.
Together with our partners we establish audacious goals (Moonshots) to work towards within healthcare. Then we search for innovators in digital health that can work with us and our partners to achieve those Moonshots. We help them find each other, create business partnerships and facilitate their relationship through collaboration.
Our partners are Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank, EY, SoftServe, and Hermitage Medical Clinic.
I worked closely with the Symyx CEO to position the company as a pure-play software company for M&A. Here is a presentation that I developed and produced for the CEO to present at the JP Morgan Healthcare Conference, the Jefferies Global Healthcare Services Conference and to selected investment banks in early 2010. On April 5, 2010, Symyx announced that it would merge with Accelrys, and the merger was completed on July 1, 2010.
According to the website Investopedia, venture capital is a kind of private equity funding that is given by investors to new enterprises and small businesses that the investors feel have the potential for long-term development. In general, it is derived from wealthy investors, investment banks, and many other financial entities.
Strong public markets and high demand for disruptive tech are continuing to drive high valuations for technology companies. Join Corum Group’s research team for a look at the key deals, trends and valuations across all six tech sectors and 30 subsectors. What sectors are getting the highest valuations? What are acquirers after? How long will these good times continue? We’ll address all these questions and more—plus, a look at key questions of succession planning. What should you be doing before, during and after a tech M&A transaction to ensure that the value you have created goes where it is supposed to?
Food Packaging Companies PPT: Business Opportunity & OverviewIMARC Group
Food packaging assists in preserving and transporting food products to their desired location without affecting their taste or quality. It also aids in protecting food products from bacteria, spillage, moisture and toxins.
From Startup to Blue Chip: The Success Story of Gilead Sciences Inc.RobertsDissertation
"Gilead Sciences (GILD) is a biotechnology company that generally focuses on antiviral drugs and therapies for HIV, hepatitis B and influenza. The company was founded in 1987 by Michael Riordan, a medical doctor who went to Harvard."
Investopedia, 2015.
USA Medical Device report 2015. In this report you can find the detail information about USA medical device industry with Merger and acquisition , Research & Development, Geographical breakdown for U.S. medical device sector.
Tech M&A Monthly: Ten Steps to Successfully Sell Now - May 2013Corum Group
Record cash, strong public markets and disruptive technology are all helping make this the best time to sell a software or related tech firm since 1999. But how do you take advantage? In this special webcast, Corum CEO Bruce Milne will present "10 Steps To Successfully Sell Now" drawing on his three decades of experience selling technology companies to help you translate your hard work and technical genius into real personal wealth, at one of the most opportune times in recent history.
HealthXL is the global clearing house for innovation in healthcare. We catalyse collaboration between leading brands in healthcare and the most exciting tech companies to improve the lives of millions of people.
Together with our partners we establish audacious goals (Moonshots) to work towards within healthcare. Then we search for innovators in digital health that can work with us and our partners to achieve those Moonshots. We help them find each other, create business partnerships and facilitate their relationship through collaboration.
Our partners are Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank, EY, SoftServe, and Hermitage Medical Clinic.
I worked closely with the Symyx CEO to position the company as a pure-play software company for M&A. Here is a presentation that I developed and produced for the CEO to present at the JP Morgan Healthcare Conference, the Jefferies Global Healthcare Services Conference and to selected investment banks in early 2010. On April 5, 2010, Symyx announced that it would merge with Accelrys, and the merger was completed on July 1, 2010.
According to the website Investopedia, venture capital is a kind of private equity funding that is given by investors to new enterprises and small businesses that the investors feel have the potential for long-term development. In general, it is derived from wealthy investors, investment banks, and many other financial entities.
Strong public markets and high demand for disruptive tech are continuing to drive high valuations for technology companies. Join Corum Group’s research team for a look at the key deals, trends and valuations across all six tech sectors and 30 subsectors. What sectors are getting the highest valuations? What are acquirers after? How long will these good times continue? We’ll address all these questions and more—plus, a look at key questions of succession planning. What should you be doing before, during and after a tech M&A transaction to ensure that the value you have created goes where it is supposed to?
The key differences between the MDR and IVDR in the EUAllensmith572606
In the European Union (EU), two significant regulations have been introduced to enhance the safety and effectiveness of medical devices – the In Vitro Diagnostic Regulation (IVDR) and the Medical Device Regulation (MDR).
https://mavenprofserv.com/comparison-and-highlighting-of-the-key-differences-between-the-mdr-and-ivdr-in-the-eu/
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
2. Jeffrey Bezos, Amazon
Amazon.com, Inc. is an American electronic commerce and cloud
computing company that was founded on July 5, 1994 by Jeff Bezos and is based
in Seattle, Washington. The tech giant is the largest Internet-based retailer in the
world by total sales and market capitalization. Amazon.com started as an
online bookstore and later diversified to sell DVDs, Blurays, CDs, video
downloads/streaming, MP3 downloads/streaming, audio
book downloads/streaming, software, video games, electronics, apparel, furniture,
food, toys, and jewelry. The company also produces consumer electronics—
notably, Kindle e-readers, Fire tablets, Fire TV, and Echo—and is the world's
largest provider of cloud infrastructure services.
3. John Martin, Gilead
Sciences
Gilead Sciences is an American biopharmaceutical company that discovers,
develops and commercializes therapeutics. For many years since the company
was founded, the company concentrated primarily on antiviral drugs used in the
treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired
two companies which were developing drugs to treat patients with pulmonary
diseases. The company currently produces a range of commercially available
products, most notably the Hepatitis C drugs.
Headquartered and founded in Foster City, California, Gilead has operations in
North America, Europe and Australia. As of the end of 2015, the company had
approximately 7,900 full-time employees.Gilead is a member of the NASDAQ
Biotechnology Index and the S&P 500.
4. John Chambers, Cisco
Systems
Cisco Systems, Inc. (known as Cisco) is an
American multinational technology conglomerate headquartered in San Jose,
California, in the center of Silicon Valley, that develops, manufactures, and
sells networking hardware, telecommunications equipment, and other high-
technology services and products.[4] Through its numerous acquired subsidiaries,
such as OpenDNS, WebEx, and Jasper, Cisco specializes into specific tech markets,
such as Internet of Things (IoT), domain security, and energy management.
Cisco is the largest networking company in the world. The stock was added to
the Dow Jones Industrial Average on June 8, 2009, and is also included in the S&P
500 Index, the Russell 1000 Index, NASDAQ-100 Index and the Russell 1000
Growth Stock Index.
5. David Pyott, Allergan
Allergan, Inc. is a global pharmaceutical company focused on eye care,
neurosciences, medical dermatology, medical aesthetics, breast enhancement,
obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated
in 1950 and became a public company in 1970. Allergan became a publicly traded
company in 1970 and was acquired by SmithKline Beckman for $259 million in
1980.[3] After generating $756 million in revenue and $80 million in profit in 1988,
Allergan was spun-off by SmithKline Beckman in 1989.
6. David Simon, Simon Property
Group
Simon Property Group, Inc. is an American commercial real estate company in
the United States and the largest real estate investment trust (REIT). It is also the
largest shopping mall operator in America.
The company is a fully integrated real estate company which operates from five
retail real estate platforms: regional malls, Premium Outlet Centers, The Mills,
community/lifestyle centers and international properties. It currently owns or has
an interest in more than 325 properties comprising approximately 241,000,000
square feet (22,400,000 m2) of gross leasable area in North America and Asia.
The company is headquartered in Indianapolis, Indiana and employs more than
5,000 people worldwide. It is publicly traded on the NYSE under the symbol SPG
and is part of the S&P 100.
7. Lars Rebien Sørensen, Novo
Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company headquartered
in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or
offices in 75 countries. Novo Nordisk is controlled by majority shareholder, Novo
Holdings A/S, which holds approximately 25% of its shares and a supermajority (75%)
of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services. Key
products include diabetes care medications and devices. Novo Nordisk is also
involved with hemostasis management, growth hormone therapy and hormone
replacement therapy. The company makes several drugs under various brand names,
including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza.
8. Hugh Grant, Monsanto
Monsanto Company is a publicly traded
American multinational agrochemical and agricultural
biotechnology corporation. It is headquartered in Creve
Coeur, Greater St. Louis, Missouri. Monsanto is a leading
producer of genetically engineered (GE) seed and Roundup,
a gly phosate-based herbicide.
Monsanto has agreed to accept Bayer's offer to purchase the
company for $66 billion ($128/share) in September 2016, and
the deal is currently pending regulatory approval.
9. J. Michael Pearson,
Valeant Pharmaceuticals
Valeant Pharmaceuticals International, Inc. is a
multinational specialty pharmaceutical company based
in Laval, Quebec, Canada. Valeant develops, manufactures
and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal
disorders, eye health, neurology and branded generics.
Valeant owns Bausch & Lomb, one of the largest
manufacturers of contact lenses.
Valeant grew quickly with a series of mergers and
acquisitions under the leadership of J. Michael Pearson and
for a short period of time in 2015 was the most valuable
company in Canada. Valeant was described as a platform
company that grows by systematically acquiring other
companies. Valeant acquired Salix Pharmaceuticals for $14.5
billion in 2015. Valeant tried to
acquire Actavis and Cephalon and merge with Allergan, but
failed.
10. Mark Donegan,
Precision Castparts
Precision Castparts Corp. is an American industrial goods and metal
fabrication company that manufactures investment castings, forged components,
and airfoil castings for use in the aerospace, industrial gas turbine, and defense
industries. In 2009 it ranked 362nd on the Fortune 500 list, and 11th in the
aerospace and defense industry. In 2015 it ranked 322nd overall and 9th in the
aerospace and defense industry. In 2014 it ranked 133rd on the S&P 500 based on
market capitalization. In January 2016, the company became
a subsidiary of Berkshire Hathaway. Before that event, it used to be one of the three
Fortune 500 companies headquartered in Oregon.
11. William
Doyle, PotashCorp
The Potash Corporation of Saskatchewan, also
known as PotashCorp, is a Canadian corporation
based in Saskatoon, Saskatchewan. The company is
the world's largest potash producer and the third
largest producer of nitrogen and phosphate, three
primary crop nutrients used to produce fertilizer. At the
end of 2011, the company controlled twenty percent of
the world's potash production capacity, two percent of
nitrogen production capacity and five percent of
phosphate supply